Skip to content

Investigation of the effect of direct hemoperfusion with polymyxin B-immobilized fiber on steroid resistant drug-induced lung injury.

Investigation of the effect of direct hemoperfusion with polymyxin B-immobilized fiber on steroid resistant drug-induced lung injury. - Investigation of the effect of direct hemoperfusion with polymyxin B-immobilized fiber on steroid resistant drug-induced lung injury.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000017263
Enrollment
20
Registered
2015-04-27
Start date
2015-04-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid resistant drug-induced lung injury

Interventions

polymyxin B-immobilized fiber column I do for 2 days. A principle is performed for more than 6 hours per once.

Sponsors

Graduate School of Medicine, Osaka City University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)PaO2 is less than 80 Torr by the patient diagnosed as steroid treatment-resistant drug-induced lung injury.. mild PaO2 >= 80 Torr. moderate 60 Torr<= PaO2<= 80 Torr severe PaO2 < 60 Torr( PaO2/FiO2 < 300). 2) Patients who received PMX-DPH evaluated with P/F ratio.( P/F ratio is less than 300 or less than 60 mmHg of PaO2 under room air inspiration)

Exclusion criteria

Exclusion criteria: 1) pregnant woman, lactating woman or patient with a possibility of the pregnancy 2) The patients who has the past of allergy to blood purification and extracorporeal circulation method of treatment 3) Other non-approval medical equipment or the patient who participates in a clinical trial of medicine approving ly. 4) The patients for whom the value of this clinical study is difficult for a terminal cancer's, chronic renal insufficiency's and death's within 7 days being predicted 5) The patients who could admit clear pulmonary infection, pneumothorax, pulmonary embolism and heart failure by a clinical judgement 6) The patients who has an experience of PMX-DPH before agreement acquisition 7) The patients who judged that an implementation responsibility doctor or an allotment doctor was unsuitable

Design outcomes

Primary

MeasureTime frame
P / F ratio at 48 hours after PMX treatment.

Countries

Japan

Contacts

Public ContactHiroshi Kamoi

Graduate School of Medicine, Osaka City University department of respiratory medcine

hiro-kamoi@med.osaka-cu.ac.jp06-6645-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026